Compare · BDX vs KIDS
BDX vs KIDS
Side-by-side comparison of Becton Dickinson and Company (BDX) and OrthoPediatrics Corp. (KIDS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and KIDS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $48.98B, about 86.5x KIDS ($566.1M).
- Over the past year, BDX is down 6.4% and KIDS is up 11.6% - KIDS leads by 18.1 points.
- KIDS has been more active in the news (8 items in the past 4 weeks vs 6 for BDX).
- BDX has more recent analyst coverage (25 ratings vs 8 for KIDS).
- Company
- Becton Dickinson and Company
- OrthoPediatrics Corp.
- Price
- $176.39-1.91%
- $21.54-0.62%
- Market cap
- $48.98B
- $566.1M
- 1M return
- -2.75%
- -11.23%
- 1Y return
- -6.44%
- +11.64%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2017
- News (4w)
- 6
- 8
- Recent ratings
- 25
- 8
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
OrthoPediatrics Corp.
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
Latest BDX
- EVP & Chief Financial Officer Roque Vitor covered exercise/tax liability with 190 shares, decreasing direct ownership by 2% to 8,041 units (SEC Form 4) (withholding tax)
- EVP, Chief Revenue Officer Feld Michael sold $31,101 worth of shares (165 units at $188.49) as part of a pre-agreed trading plan, decreasing direct ownership by 0.83% to 19,720 units (SEC Form 4)
- BD Extends Leadership in Advanced Tissue Regeneration Through Continued Clinical Innovation
- BD to Present at Wells Fargo 21st Annual Healthcare Conference
- EVP, Chief Revenue Officer Feld Michael covered exercise/tax liability with 1,049 shares, decreasing direct ownership by 5% to 19,885 units (SEC Form 4) (for withholding tax)
- BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire
- Chairman, CEO and President Polen Thomas E Jr exercised 43,278 shares at a strike of $167.25, returned $7,238,310 worth of shares to the company (39,126 units at $185.00) and sold $768,120 worth of shares (4,152 units at $185.00) as part of a pre-agreed trading plan (SEC Form 4)
- EVP and President, EMEA Goette Roland sold $440,888 worth of shares (2,438 units at $180.84), decreasing direct ownership by 14% to 14,856 units (SEC Form 4)
- BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
- SEC Form 4 filed by Director Huffines Robert Luther
Latest KIDS
- Director Pelizzon David R sold $6,352,773 worth of shares (302,369 units at $21.01) (SEC Form 4)
- Large owner Squadron Capital Llc sold $7,761,194 worth of shares (336,831 units at $23.04) (SEC Form 4)
- Large owner Pritzker Jennifer N. sold $7,761,194 worth of shares (336,831 units at $23.04) (SEC Form 4)
- Director Pelizzon David R sold $7,761,194 worth of shares (336,831 units at $23.04) (SEC Form 4)
- Large owner Pritzker Jennifer N. sold $943,302 worth of shares (38,300 units at $24.63) (SEC Form 4)
- Large owner Squadron Capital Llc sold $943,302 worth of shares (38,300 units at $24.63) (SEC Form 4)
- Director Pelizzon David R sold $943,302 worth of shares (38,300 units at $24.63) (SEC Form 4)
- OrthoPediatrics Announces Full Commercial Launch of 3P™ Pediatric Plating Platform® Hip System Following More Than 350 Successful Implantations
- SEC Form 10-Q filed by OrthoPediatrics Corp.
- OrthoPediatrics Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits